semaglutide and liver disease Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty disease? The weight-loss-independent hepatoprotective benefits of

Ozempic is FDA approved for type 2 diabetes management and has extensive data supporting its ability to reduce HbA1c by 1.0% to 1.8% depending on baseline levels and dose

Semaglutide showed 73% reduction in diabetes progression

Several active research areas include: Metabolic dysfunction-associated steatotic liver disease (MASLD) : Multiple trials are evaluating semaglutide's effects on liver fat content and biomarkers, with preliminary data suggesting potential benefits in reducing hepatic steatosis and improving liver enzyme profiles Chronic kidney disease : Studies examining renal outcomes in patients with type 2 diabetes and established kidney disease, building on secondary analyses from SUSTAIN 6 showing reduced progression of diabetic nephropathy Obstructive sleep apnea : Ongoing trials investigating whether weight loss achieved with semaglutide improves sleep apnea severity and related cardiovascular outcomes Addiction and substance use disorders : Early-phase research exploring GLP-1 receptor agonists' potential effects on reward pathways and addictive behaviors, though this remains highly preliminary Alzheimer's disease and cognitive function : Preclinical evidence suggesting neuroprotective properties has prompted clinical trials examining cognitive outcomes in at-risk populations Researchers are also investigating combination therapies , such as cagrilintide plus semaglutide (CagriSema), which is currently under development

While all of this is going on, GLP-1 is also reducing the amount of glucagon that the pancreas produces

In many cases, Semaglutide is part of a long-term weight management plan rather than a short course

Curr Cardiol Rep